Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors

Por Michaela Waibel, Vanessa S. Solomon, Deborah A. Knight, Rachael A. Ralli, Sang-Kyu Kim, Kellie-Marie Banks, Eva Vidacs, Clemence Virely, Keith C.S. Sia, Lauryn S. Bracken, Racquel Collins-Underwood, Christina Drenberg, Laura B. Ramsey, Sara C. Meyer, Megumi Takiguchi, Ross A. Dickins, Ross Levine, Jacques Ghysdael, Mark A. Dawson, Richard B. Lock, Charles G. Mullighan, Ricky W. Johnstone
Publicado em 2013-11-01